Medicines Co., Chiesi deal

Chiesi will purchase Medicines Co.’s non-core cardiovascular assets, including Cleviprex clevidipine, Kengreal cangrelor and the company’s rights to ready to use argatroban. Medicines Co. will receive $260 million cash up front when the deal closes, which is expected next quarter. The company is eligible for up to $480 million in sales milestones. Chiesi will assume up to $50 million in Medicines Co.’s milestone obligations and pay about $2 million for product inventory. ...